Sign in5 stories
Stockholders approved eight of twelve agenda items on September 17, 2026, but the company put off votes on four proposals until October 1 while it awaits Nasdaq's response on a listing application.
SEC filing
The September 16, 2026 amendments reclassify milestone warrant liabilities as equity, addressing a Nasdaq stockholders' equity shortfall tied to the Azora merger financing.
SEC filing
The company issued an option for 307,814 shares outside its equity plans as an inducement for a new hire, per an 8-K filed for events on August 19, 2026.
SEC filing
Adial says it remains on track to file an IND for its ulcerative colitis candidate AT177 in the first half of 2027 after acquiring Azora Therapeutics.
SEC filing
The company said it expects to swap out its top executives and reshape its board if stockholders approve certain proposals at the September 17, 2026 meeting.
SEC filing